Faeth Therapeutics, Inc. (FTH) - Total Assets
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) holds total assets worth $189.31 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Faeth Therapeutics, Inc. for how efficiently the company converts equity into cash flow.
Faeth Therapeutics, Inc. - Total Assets Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See FTH stock price for real-time trading data and today's change.
Faeth Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Faeth Therapeutics, Inc.'s total assets of $189.31 Million consist of 93.9% current assets and 6.1% non-current assets. Explore working capital position of Faeth Therapeutics, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Faeth Therapeutics, Inc.'s current assets represent 93.9% of total assets in 2025, an increase from 69.2% in 2018.
- Cash Position: Cash and equivalents constituted 37.9% of total assets in 2025, up from 35.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Faeth Therapeutics, Inc. Competitors by Total Assets
Key competitors of Faeth Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Seegene Inc
KQ:096530
|
Korea | ₩1.27 Trillion |
Faeth Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.69 | 7.64 | 42.22 |
| Quick Ratio | 19.69 | 7.64 | 42.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $179.08 Million | $25.70 Million | $161.69 Million |
Faeth Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Faeth Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.72 |
| Latest Market Cap to Assets Ratio | 28.90 |
| Asset Growth Rate (YoY) | -49.5% |
| Total Assets | $22.90 Million |
| Market Capitalization | $661.77 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Faeth Therapeutics, Inc.'s assets at a significant premium (28.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Faeth Therapeutics, Inc.'s assets decreased by 49.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual total assets of Faeth Therapeutics, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.90 Million | -49.51% |
| 2024-12-31 | $45.36 Million | -39.01% |
| 2023-12-31 | $74.37 Million | -37.17% |
| 2022-12-31 | $118.38 Million | -22.74% |
| 2021-12-31 | $153.22 Million | +615.07% |
| 2020-12-31 | $21.43 Million | +1660.72% |
| 2019-12-31 | $1.22 Million | -34.22% |
| 2018-12-31 | $1.85 Million | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more